Discovery is major step towards a stem cell replacement therapy for Duchenne Muscular Dystrophy
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
The study was published in the journal Nature Cell Biology by senior author April Pyle, associate professor of microbiology, immunology and molecular genetics and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore dystrophin, the protein that is missing in the muscles of boys with Duchenne.
Without dystrophin, muscles degenerate and become progressively weaker. Duchenne symptoms usually begin in early childhood; patients gradually lose mobility and typically die from heart or respiratory failure around age 20. There is currently no way to reverse or cure the disease.
For years, scientists have been trying different methods that direct human pluripotent stem cells to generate skeletal muscle stem cells that can function appropriately in living muscle and regenerate dystrophin-producing muscle fibers. However, the study led by Pyle found that the current methods are inefficient; they produce immature cells that are not appropriate for modeling Duchenne in the laboratory or creating a cell replacement therapy for the disease.
“We have found that just because a skeletal muscle cell produced in the lab expresses muscle markers, doesn’t mean it is fully functional,” said Pyle. “For a stem cell therapy for Duchenne to move forward, we must have a better understanding of the cells we are generating from human pluripotent stem cells compared to the muscle stem cells found naturally in the human body and during the development process.”
By analyzing human development, the researchers found a fetal skeletal muscle cell that is extraordinarily regenerative. Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the reserchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Once they were able to isolate skeletal muscle cells using the newly identified surface markers, the research team matured those cells in the lab to create dystrophin-producing muscle fibers. The muscle fibers they created were uniformily muscle cells, but the fibers were still smaller than those found in real human muscle.
“We were missing another key component,” said Michael Hicks, lead author of the study. The skeletal muscle cells were not maturing properly, he explained. “We needed bigger, stronger muscle that also had the ability to contract.”
Once again, the team looked to the natural stages of human development for answers. Hicks discovered that a specific cell signaling pathway called TGF Beta needs to be turned off to enable generation of skeletal muscle fibers that contain the proteins that help muscles contract. Finally, the team tested their new method in a mouse model of Duchenne.
“Our long term goal is to develop a personalized cell replacement therapy using a patient’s own cells to treat boys with Duchenne,” said Hicks. “So, for this study we followed the same steps, from start to finish, that we’d follow when creating these cells for a human patient.”
First, the Duchenne patient cells were reprogrammed to become pluripotent stem cells. The researchers then removed the genetic mutation that causes Duchenne using the gene editing technology CRISPR-Cas9. Using the ERBB3 and NGFR surface markers, the skeletal muscle cells were isolated and then injected into mice at the same time a TGF Beta inhibitor was administered.
“The results were exactly what we’d hoped for,” said Pyle. “This is the first study to demonstrate that functional muscle cells can be created in a laboratory and restore dystrophin in animal models of Duchenne using the human development process as a guide.”
Further research will focus on generating skeletal muscle stem cells that can respond to continuous injury and regenerate new muscle long-term using the team’s new isolation and maturation strategy.
The Latest on: Duchenne Muscular Dystrophy
[google_news title=”” keyword=”Duchenne Muscular Dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Muscular Dystrophy: Symptoms, causes, diagnosis and treatmenton February 22, 2024 at 3:27 am
These mutations can occur in various genes, each associated with a specific type of Muscular Dystrophy. The most common types include: Duchenne Muscular Dystrophy (DMD): Caused by mutations in the ...
- Spennymoor teen cares for his brother with muscle conditionon February 21, 2024 at 10:00 pm
William described as ‘funny, caring, charming and super bright’ has selflessly taken on the role of providing care and support for his younger brother Louis, 12, who was diagnosed with Duchenne ...
- Staten Island JAR of Hope donates nearly $12K to CrimsonRise to help those with autism communicateon February 21, 2024 at 8:59 pm
STATEN ISLAND, N.Y. — JAR of Hope, an organization that raises funds to research a cure for kids with Duchenne muscular dystrophy — that’s recently expanded its mission statement to include kids on ...
- Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?on February 21, 2024 at 8:24 am
We expect Sarepta Therapeutics SRPT to beat expectations when it reports fourth-quarter and full-year 2023 results. In the last reported quarter, the company delivered an earnings surprise of ...
- Herpes-Dementia Link; How COVID Affects the Brain; FDA to Decide on Duchenne Drugon February 20, 2024 at 11:54 am
German researchers showed that SARS-CoV-2 did not persist in brain cells and supported the idea that COVID's neurologic complications may be due to inflammatory immune reactions. ( Nature Neuroscience ...
- Novel ASO screening study paves the way for duchenne muscular dystrophy (DMD) therapy advancementson February 20, 2024 at 2:11 am
This article talks about the identification of a novel ASO (AON-C19) which opens a promising new avenue for Duchenne Muscular Dystrophy (DMD) therapy development.
- Avidity Biosciences' AOC 1044 Gets FDA Rare Pediatric Disease Designationon February 20, 2024 at 1:48 am
These designations by the FDA underscore the urgent need for innovative treatments and validate the potential of AOC 1044 to address the unmet need of people living with Duchenne muscular dystrophy," ...
- Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatmenton February 19, 2024 at 4:27 am
Santhera Pharmaceuticals has announced the publication of results in the journal Neurology that support the long-term efficacy and safety profile of its Duchenne muscular dystrophy (DMD) drug, Agamree ...
- The Future of Medicine Is Unfolding Before Us. Are We Nurturing It?on February 18, 2024 at 9:02 pm
Before Eliot received his treatment, he had difficulty going up stairs. He complained about being tired after walking only a block or two, even on Halloween when candy ought to have motivated him.
- Duchenne Muscular Dystrophy Market Size Predicted To Hit USD 2.1 Billion By 2031 At 4.7% CAGR, Says AMRon February 13, 2024 at 10:33 pm
Duchenne Muscular Dystrophy Market 2024 Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healt ...
via Google News and Bing News